Summary:
Midwest Research Group is conducting a Phase 3, long-term, open-label study of the safety and tolerability of Cariprazine as an adjunctive therapy in Major Depressive Disorder.
Qualified Participants Must:
• Have a diagnosis of Major Depression
•
Have had inadequate response to 1-2 allowed antidepressant medications
Qualified Participants May Receive:
Compensation for time and travel, study medications, labs, meetings with a physician and ongoing support from research staff.